Item Type: | Article |
---|---|
Title: | Efficacy of a triple treatment with irradiation, agonistic TRAIL receptor antibodies and EGFR blockade |
Creators Name: | Niyazi, M., Marini, P., Daniel, P.T., Humphreys, R., Jendrossek, V. and Belka, C. |
Abstract: | BACKGROUND AND PURPOSE: : Since the efficacy of a single targeted agent in combination with ionizing radiation is limited by putative treatment resistances, a rationally designed triple treatment consisting of an agonistic antibody targeting either TRAIL-R1 (mapatumumab) or TRAIL-R2 (lexatumumab), radiation and an epidermal growth factor receptor-(EGFR-)inhibiting antibody (cetuximab) was tested. MATERIAL AND METHODS: : Induction of apoptosis after triple treatment was determined in Colo205, HCT116 and FaDu cells by Hoechst 33342 stain. The degree of interaction was determined by isobologram analysis. A knockout variant of HCT116 was used to examine Bax dependence of the triple treatment. The role of Akt/PKB signaling was analyzed using the phosphatidylinositol 3-kinase inhibitor LY294002. Clonogenic assays were performed to examine the effect on clonogenic survival of tumor cells. RESULTS: : A synergistic effect of radiation, cetuximab and agonistic TRAIL-R antibodies was demonstrated in cell lines derived from colorectal tumors or head-and-neck cancers. The efficacy of this multimodal approach was dependent on Bax and inhibition of Akt/PKB in the cell systems used. The results also show a positive impact on clonogenic cell death in several cell lines. CONCLUSION: : These data suggest that rationally designed multimodal therapy approaches integrating radiation with more than one targeted agent will open new perspectives in radiation oncology. |
Keywords: | Radiotherapy, TRAIL Antibodies, Mapatumumab, Lexatumumab, Cetuximab, Triple Treatment |
Source: | Strahlentherapie und Onkologie |
ISSN: | 0179-7158 |
Publisher: | Urban & Vogel |
Volume: | 185 |
Number: | 1 |
Page Range: | 8-18 |
Date: | January 2009 |
Official Publication: | https://doi.org/10.1007/s00066-009-1856-4 |
PubMed: | View item in PubMed |
Repository Staff Only: item control page